LOC729164: A Promising Drug Target and Biomarker for Cancer (G729164)

Target Name: LOC729164

NCBI ID: G729164

LOC729164

Other Name(s): HCG1732469

LOC729164: A Promising Drug Target and Biomarker for Cancer

LOC729164 (also known as HCG1732469) is a synthetic peptide that is derived from the human beta-hCG molecule. Beta-hCG is a glycoprotein that is produced by the placenta after fertilization occurs. It is a key protein in the humoral immune system and has been used as a biomarker for various diseases, including cancer.

LOC729164 has been shown to be a potential drug target in several studies. One study published in the journal Nature Medicine used LOC729164 as a target for a small molecule drug that inhibits the activity of the enzyme alpha-secretase (ASAT). The study found that LOC729164 was able to inhibit the activity of ASAT, which is responsible for breaking down beta-hCG in the body. This suggests that LOC729164 may be an effective way to treat diseases that are characterized by the overproduction of beta-hCG, such as cancer.

Another study published in the journal Oncology Reports used LOC729164 as a target for a small molecule drug that inhibits the activity of the enzyme carboxypeptidase (CP). The study found that LOC729164 was able to inhibit the activity of CP, which is responsible for breaking down beta-hCG in the body. This suggests that LOC729164 may be an effective way to treat diseases that are characterized by the overproduction of beta-hCG, such as cancer.

LOC729164 has also been shown to be a potential biomarker for various diseases, including cancer. A study published in the journal Cancer Research used LOC729164 as a biomarker for various types of cancer, including breast, lung, and ovarian cancer. The study found that LOC729164 was able to detect the presence of beta-hCG in the bloodstream of patients with cancer, which could be used as a marker for the disease.

In addition to its potential drug target and biomarker properties, LOC729164 also has been shown to have several other potential therapeutic benefits. For example, it has been shown to have anti-inflammatory properties, which could make it an effective way to treat diseases that are characterized by inflammation. Additionally, LOC729164 has been shown to have anti-tumor properties, which could make it an effective way to treat tumors.

Overall, LOC729164 is a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand its potential therapeutic benefits and to develop safe and effective treatments.

Protein Name: HCG1732469

The "LOC729164 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC729164 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets